Market Research Logo

Dermatomycoses - Pipeline Review, H2 2016

Dermatomycoses - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomycoses - Pipeline Review, H2 2016, provides an overview of the Dermatomycoses (Infectious Disease) pipeline landscape.

Dermatophytes cause fungal infections of keratinized tissues, e.g. skin, hair and nails. The organisms belong to 3 genera, Trichophyton, Epidermophyton and Microsporum. Dermatophytes may be grouped into 3 categories based on host preference and natural habitat. Anthropophilic species predominantly infect humans, geophilic species are soil based and may infect both humans and animals, zoophilic species generally infect non-human mammals.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomycoses - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dermatomycoses (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomycoses (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dermatomycoses and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.Dermatomycoses.

Dermatomycoses (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomycoses (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Dermatomycoses (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dermatomycoses (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dermatomycoses (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomycoses (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dermatomycoses (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dermatomycoses (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Dermatomycoses Overview
Therapeutics Development
Pipeline Products for Dermatomycoses - Overview
Pipeline Products for Dermatomycoses - Comparative Analysis
Dermatomycoses - Therapeutics under Development by Companies
Dermatomycoses - Therapeutics under Investigation by Universities/Institutes
Dermatomycoses - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Dermatomycoses - Products under Development by Companies
Dermatomycoses - Products under Investigation by Universities/Institutes
Dermatomycoses - Companies Involved in Therapeutics Development
Anacor Pharmaceuticals Inc
Biolab Farmaceutica Ltda
Blueberry Therapeutics Ltd
Daewoong Pharmaceutical Co Ltd
Dermala Inc
Helix BioMedix Inc
Novan Inc
Sol-Gel Technologies Ltd
TGV-Laboratories
Viamet Pharmaceuticals Inc
Vyome Biosciences Pvt Ltd
Dermatomycoses - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AN-2718 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-2603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clotrimazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dapaconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Athlete's Foot - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-06081 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-1275 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
luliconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myc-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitric oxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-208 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dermatomycoses - Dormant Projects
Dermatomycoses - Product Development Milestones
Featured News & Press Releases
Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting
Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis
Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Dermatomycoses, H2 2016
Number of Products under Development for Dermatomycoses - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Dermatomycoses - Pipeline by Anacor Pharmaceuticals Inc, H2 2016
Dermatomycoses - Pipeline by Biolab Farmaceutica Ltda, H2 2016
Dermatomycoses - Pipeline by Blueberry Therapeutics Ltd, H2 2016
Dermatomycoses - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016
Dermatomycoses - Pipeline by Dermala Inc, H2 2016
Dermatomycoses - Pipeline by Helix BioMedix Inc, H2 2016
Dermatomycoses - Pipeline by Novan Inc, H2 2016
Dermatomycoses - Pipeline by Sol-Gel Technologies Ltd, H2 2016
Dermatomycoses - Pipeline by TGV-Laboratories, H2 2016
Dermatomycoses - Pipeline by Viamet Pharmaceuticals Inc, H2 2016
Dermatomycoses - Pipeline by Vyome Biosciences Pvt Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Dermatomycoses - Dormant Projects, H2 2016
List of Figures
Number of Products under Development for Dermatomycoses, H2 2016
Number of Products under Development for Dermatomycoses - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report